XML 24 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Other Income
 12 Months Ended
Sep. 30, 2017
Component of Operating Income [Abstract]  
Other Income
Note 3 Other Income

 

Grant Income

 

On June 19, 2015, the Company was awarded grant funding in the amount of $286,455. The grant has been received in exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential treatment for Parkinson’s disease.

 

The grant income was deferred and amortized to other income over the related commitment period as the related research and development expenditures were incurred. During the year ended September 30, 2017, the Company recognized $140,942 (2016: $141,195; 2015: $Nil) of this grant on its statement of operations within grant income.

 

Research and development tax incentive

 

During the year ended September 30, 2017, the Company received other income of $2,022,902 (2016: $571,093, 2015: $Nil) in respect of a research and development incentive program offered by the Australian government.